Results 221 to 230 of about 10,318 (317)

Optimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM. [PDF]

Diabetes Metab Syndr Obes
Ghosal S, Ghosal A.
europepmc   +1 more source

Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4344-4351, May 2026.
ABSTRACT Aims Kidney and cardiovascular diseases are highly prevalent among patients with Type 1 diabetes. To date, no randomised clinical trial has reported on the impact of novel cardio‐kidney‐metabolic (CKM) therapies (GLP‐1RA and SGLT2i) on kidney function in this population.
M. Luiza Caramori, Enrico Repetto, Christopher Perkins, Ambarish Pandey, Peter Rossing   +4 more
wiley   +1 more source

Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes. [PDF]

NPJ Breast Cancer
Hundal J, Ashruf OS, Li H, Basen-Engquist K, Kaelber DC, Sukumar JS.   +5 more
europepmc   +1 more source

7440 Both GLP-1RA and SGLT2i medications are associated with lower depression scores in veterans compared to metformin and insulin [PDF]

Shannen Nicole Dean Ubalde, Halle Cann, Layal Esper, Joseph Powell, Kristin Meyer, Sabyasachi Sen   +5 more
openalex   +1 more source

Συστηματική ανασκόπηση: Ο ρόλος των GLP-1RAs στην καρδιαγγειακή νόσο / Systematic review: The role of GLP-1RAs in CVD

Ιστορικό: Οι αγωνιστές του υποδοχέα της γλυκαγόνης-1 (GLP-1RA) είναι καθιερωμένοι παράγοντες μείωσης της γλυκόζης και απώλειας βάρους, ωστόσο το πλήρες καρδιαγγειακό τους δυναμικό παραμένει ασαφές. Σκοπός: Να συντεθεί τεκμηρίωση σχετικά με τις καρδιαγγειακές επιδράσεις των μακράς δράσης GLP-1RA, με έμφαση στις σοβαρές ανεπιθύμητες καρδιαγγειακές ...
openaire   +1 more source

Clinical significance of renal histological diagnosis in patients with type 2 diabetes and proteinuria atypical for diabetic nephropathy

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 781-790, May 2026.
ABSTRACT Background/Aim Most patients with proteinuria are considered to have typical diabetic nephropathy (DN). However, when proteinuria occurs without diabetic retinopathy, with hematuria, or persists despite strict glycemic and blood pressure control, it is considered atypical for DN and warrants further evaluation for non‐DN via kidney biopsy ...
Shogo Kuwagata, Masami Chin‐Kanasaki, Aki Yamada, Tomonori Sakae, Nahomi Ishimoto, Yoshimi Imamura‐Uehara, Kosuke Yamahara, Mako Yasuda‐Yamahara, Sho Sugahara, Yuki Tanaka‐Sasaki, Natsumi Kuwata, Kimihiro Nishimura, Koichiro Murata, Itsuko Miyazawa, Shogo Ida, Natsuko Ohashi, Shinji Kume   +16 more
wiley   +1 more source

Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes. [PDF]

Diabetes Care
Zhang D, Gencerliler N, Mukhopadhyay A, Blecker S, Grams ME, Wright DR, Wang VH, Rajan A, Butt E, Shin JI, Xu Y, Chhabra KR, Divers J.   +12 more
europepmc   +1 more source

Impact of renal function on antidiabetic drug selection in Japan: A real‐world analysis using the J‐DREAMS database

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 801-809, May 2026.
Using a large Japanese real‐world database, we examined antidiabetic drug selection in first and second therapy stratified by renal function and study period. The earlier initiation of SGLT2 inhibitors and GLP‐1 receptor agonists increased over time, particularly in second therapy, with prescribing patterns increasingly aligned across renal function ...
Masashi Kubota, Mitsuru Ohsugi, Kohjiro Ueki   +2 more
wiley   +1 more source

Effects of GLP‐1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aims GLP‐1 receptor agonists (GLP‐1RAs) promote significant weight loss, but their impact on muscle mass, strength, and quality in metabolic dysfunction–associated steatotic liver disease (MASLD), a condition prone to muscle impairment, remains uncertain.
Fernando Iorra, Tanya Jayakar, Michael Yee, Mark R. Thursz, Beatriz D. Schaan, Pinelopi Manousou   +5 more
wiley   +1 more source

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON‐CABG CardioLink‐5 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4376-4381, May 2026.
Hwee Teoh, Subodh Verma, G. B. John Mancini, Adrian Quan, Michael Szarek, Randi Elituv, Meena Verma, Elizabeth Misner, Aishwarya Krishnaraj, Peter Jüni, Michael J. Koren, Stephen J. Nicholls, Deepak L. Bhatt, C. David Mazer, Lawrence A. Leiter   +14 more
wiley   +1 more source